Ainos Expands Global IP Portfolio to 123 Patents with Seven New AI Nose Patents
Ainos (NASDAQ:AIMD) has expanded its intellectual property portfolio with seven new AI Nose patents across Europe, Germany, Taiwan, and China, bringing its total patent count to 123 active patents. The company's AI-powered scent digitization platform, AI Nose, is being developed for multiple industries including healthcare, semiconductors, smart factories, and robotics.
The technology enables machines to detect and analyze scents, with applications ranging from patient monitoring in healthcare to process optimization in semiconductor manufacturing. Under CEO Eddy Tsai's leadership, Ainos is advancing its SmellTech-as-a-Service business model and maintaining its trajectory toward 2026 commercialization goals.
[ "Expansion of patent portfolio to 123 patents across major markets", "Broad application potential across multiple high-value industries", "Strong IP protection creating competitive barriers", "Clear commercialization timeline with 2026 milestone" ]Ainos ha ampliato il portafoglio di proprietà intellettuale con sette nuovi patent AI Nose in Europa, Germania, Taiwan e Cina, portando il totale a 123 brevetti attivi. La piattaforma di digitalizzazione degli odori basata su IA, AI Nose, è in sviluppo per settori tra cui sanità, semiconduttori, fabbriche intelligenti e robotica.
La tecnologia consente alle macchine di rilevare e analizzare gli odori, con applicazioni che vanno dal monitoraggio dei pazienti in sanità all’ottimizzazione dei processi nella produzione di semiconduttori. Sotto la guida del CEO Eddy Tsai, Ainos avanza nel modello di business SmellTech-as-a-Service e mantiene la traiettoria verso gli obiettivi di commercializzazione del 2026.
Ainos (NASDAQ:AIMD) ha ampliado su cartera de propiedad intelectual con siete nuevas patentes de AI Nose en Europa, Alemania, Taiwán y China, elevando el total de patentes activas a 123. La plataforma de digitalización de aromas impulsada por IA, AI Nose, se está desarrollando para sectores como sanidad, semiconductores, fábricas inteligentes y robótica.
La tecnología permite a las máquinas detectar y analizar olores, con aplicaciones que van desde el monitoreo de pacientes en sanidad hasta la optimización de procesos en la fabricación de semiconductores. Bajo la dirección del CEO Eddy Tsai, Ainos avanza en su modelo de negocio SmellTech-as-a-Service y mantiene la trayectoria hacia los objetivos de comercialización para 2026.
Ainos는 유럽, 독일, 대만, 중국에서 7건의 새로운 AI Nose 특허를 포함해 지적재산 포트폴리오를 확장하여 총 123건의 활성 특허를 확보했습니다. AI Nose 플랫폼은 헬스케어, 반도체, 스마트 팩토리, 로봇공학 등 여러 산업을 대상으로 개발 중입니다.
이 기술은 기계가 향기를 감지하고 분석할 수 있게 하며, 의료 분야의 환자 모니터링에서부터 반도체 제조 공정의 최적화에 이르기까지 응용 분야가 있습니다. 에디 차이 CEO의 리더십 아래, Ainos는 SmellTech-as-a-Service 비즈니스 모델을 추진하고 2026년 상용화 목표를 향한 궤도를 유지하고 있습니다.
Ainos (NASDAQ:AIMD) a étendu son portefeuille de propriété intellectuelle avec sept nouveaux brevets AI Nose couvrant l'Europe, l'Allemagne, Taïwan et la Chine, portant le total à 123 brevets actifs. La plateforme de numérisation des odeurs basée sur l’IA, AI Nose, est en développement pour divers secteurs, dont la santé, les semiconducteurs, les usines intelligentes et la robotique.
La technologie permet aux machines de détecter et d’analyser les odeurs, avec des applications allant du suivi des patients dans le domaine de la santé à l’optimisation des processus de fabrication des semiconducteurs. Sous la direction du PDG Eddy Tsai, Ainos fait progresser son modèle SmellTech-as-a-Service et poursuit son chemin vers les objectifs de commercialisation en 2026.
Ainos (NASDAQ:AIMD) hat sein Portfolio an geistigem Eigentum um sieben neue AI Nose-Patente in Europa, Deutschland, Taiwan und China erweitert und die Anzahl aktiver Patente auf 123 erhöht. Die KI-gestützte Geruchs-Digitalisierungsplattform AI Nose wird für verschiedene Branchen entwickelt, darunter Gesundheitswesen, Halbleiter, intelligente Fabriken und Robotik.
Die Technologie ermöglicht es Maschinen, Gerüche zu erkennen und zu analysieren, mit Anwendungen von der Patientenüberwachung im Gesundheitswesen bis zur Prozessoptimierung in der Halbleiterfertigung. Unter der Führung von CEO Eddy Tsai treibt Ainos sein SmellTech-as-a-Service-Geschäftsmodell voran und bleibt auf Kurs zu den kommerziellen Zielen 2026.
أينوس (المدرجة في ناسداك: AIMD) وسّعت محفظة الملكية الفكرية لديها بإضافة سبع براءات اختراع AI Nose جديدة عبر أوروبا وألمانيا وتايوان والصين، ليصل مجموع البراءات النشطة إلى 123 براءة. منصة AI Nose الرقمية لقراءة الروائح مطورة لعدة قطاعات بما في ذلك الرعاية الصحية، والدوائر المتكاملة (الـSemiconductors)، والمصانع الذكية، والروبوتات.
التقنية تتيح للآلات اكتشاف الروائح وتحليلها، وتطبيقاتها تتراوح من مراقبة المرضى في الرعاية الصحية إلى تحسين العمليات في تصنيع أشباه الموصلات. تحت قيادة الرئيس التنفيذي إيدي ساي، تتقدم أينوس بنموذج SmellTech-as-a-Service وتواصل مسارها نحو أهدافها للتسويق في 2026.
Ainos（纳斯达克股票代码：AIMD）通过在欧洲、德国、台湾和中国推出 七项 AI Nose 专利，扩展了知识产权组合，使在研专利总数达到 123 件。公司基于 AI 的气味数字化平台 AI Nose 正在面向医疗、半导体、智能工厂和机器人等多行业开发。
该技术使机器能够检测与分析气味，应用覆盖从医疗领域的患者监护到半导体制造过程的工艺优化。在 CEO Eddy Tsai 的领导下，Ainos 正推进 SmellTech-as-a-Service 商业模式，并保持实现 2026 年商业化目标的轨道。
- None.
- Technology still in pre-commercialization phase
- Revenue generation yet to begin
Insights
Ainos strengthens market position with 7 new AI Nose patents across key markets, expanding total IP to 123 patents while advancing commercialization strategy.
Ainos has significantly bolstered its intellectual property position in the emerging digital olfaction space, securing seven additional patents across strategic markets including Europe, Germany, Taiwan, and China. This expansion brings their total patent count to 123, creating a formidable barrier to competition in the AI-powered scent digitization market.
The company's patent strategy demonstrates sophisticated IP portfolio management, with coverage across all major global markets including the US, Europe, Germany, Japan, Taiwan, and China. This comprehensive geographic protection is critical for technologies with global market potential.
What's particularly noteworthy is how Ainos has structured its IP moat to protect multiple aspects of its technology - from product design and internal structures to system configurations and core operating principles. This layered approach to IP protection significantly increases the difficulty for competitors to develop alternative solutions without infringement.
The company is targeting high-value commercial applications across strategic sectors: healthcare monitoring, semiconductor manufacturing optimization, smart factory automation, and robotics integration. Each of these markets represents substantial revenue potential, with digital olfaction solving genuine industrial challenges like maintenance prediction, safety monitoring, and process optimization.
Ainos appears to be executing a well-defined commercialization roadmap, with specific milestones targeted for 2026. Their "SmellTech-as-a-Service" business model suggests a recurring revenue approach rather than one-time hardware sales, potentially creating more predictable and higher-margin revenue streams as adoption increases across their target industries.
New Patents in Europe, Germany, Taiwan, and China Strengthen SmellTech Leadership
Expanding IP Moat to Accelerate Commercialization of AI Nose Across Healthcare, Semiconductors, and Robotics
SAN DIEGO, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced it has secured seven new patents in Europe, Germany, Taiwan and China that strengthen its AI Nose digital olfaction platform and its applications in robotics. With these additions, Ainos now holds 123 active patents across key technologies, covering the U.S., Europe, Germany, Japan, Taiwan, and China.
AI Nose Expands Across High-Value Applications
Ainos' AI Nose platform is rapidly broadening its commercial opportunities across multiple industries:
Healthcare and Senior Care: Provides real-time detection and continuous monitoring to protect patients and seniors.
Semiconductors: Detects subtle scent anomalies to optimize processes, improve yield, and enhance safety.
Smart Factories: Equips fully automated production lines with the ability to "smell," enabling efficient maintenance and greater process stability.
Robotics: Adds the long-missing sense of smell to machines, allowing robots to "see, hear, touch-and now smell" for service, security, disaster response, and smart city applications.
"AI Nose digitizes smell, the critical human sense that has been absent from machines-until now," said Eddy Tsai, Chairman, President, and CEO of Ainos. "Our patents form a deep moat around AI Nose technology, covering product design, internal structures, system configurations, and core operating principles. This robust protection secures our leadership in AI-powered electronic nose and accelerates commercial adoption across healthcare, smart manufacturing, automation, and robotics."
Ainos has also filed additional patent applications in major markets to expand its IP moat. The Company is advancing its SmellTech-as-a-Service business model and remains on track to achieve its 2026 commercialization milestone, bringing digital olfaction into the era of AI and smart manufacturing.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
How many patents does Ainos (NASDAQ:AIMD) now hold for its AI Nose technology?
What are the main applications of Ainos' AI Nose technology?
When does Ainos plan to commercialize its AI Nose technology?
What markets are covered by Ainos' AI Nose patents?
What is the purpose of Ainos' AI Nose technology?
